secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2026-09-14T20:16:45+00:00
Accession:  0001420720-26-000028
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio updates corporate presentation focused on antibodies for obesity and cardiometabolic diseases
--------------------------------------------------------------------------------

- Corporate presentation dated September 2026 filed as Exhibit 99.1; highlights breakthrough antibodies for obesity and cardiometabolic diseases.
- No specific pipeline milestones, financial figures, or clinical data disclosed in the filing excerpt.
- Filing notes forward-looking statements and risks including regulatory approvals, financing, and Nasdaq listing maintenance.
- Presentation updated for meetings with investors, analysts, and others; no other material events reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000028/0001420720-26-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000028/ibio-20260914x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-26-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer